Top

European Archives of Psychiatry and Clinical Neuroscience

Published in:

01-11-2010 | Review

Anticholinergic drug use and risk for dementia: target for dementia prevention

Authors: Frank Jessen, Hanna Kaduszkiewicz, Moritz Daerr, Horst Bickel, Michael Pentzek, Steffi Riedel-Heller, Michael Wagner, Siegfried Weyerer, Birgitt Wiese, Hendrik van den Bussche, Karl Broich, Wolfgang Maier

Published in: European Archives of Psychiatry and Clinical Neuroscience | Special Issue 2/2010

Abstract

An increasing number of longitudinal cohort studies have identified a risk increase for dementia by the chronic use of drugs with anticholinergic properties. The respective data from the German Study on Aging, Cognition and Dementia in Primary Care Patients (AgeCoDe) also showing risk increase (hazard ratio = 2.081) are reported here. The mechanisms by which the risk increase is transported are still unknown. Irritation of compensated alterations of cholinergic transmission at the pre-dementia stage of Alzheimer’s disease (AD) or acceleration of neuroinflammation by disturbance of the anti-inflammatory effect of cholinergic innervation are discussed. In terms of dementia prevention, centrally acting anticholinergic drugs should be strictly avoided, because of long-term dementia risk increase in addition to acute negative effects on cognition.

in t’ Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, Breteler MM, Stricker BH (2001) Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med 345:1515–1521CrossRef

Zandi PP, Anthony JC, Hayden KM, Mehta K, Mayer L, Breitner JC, Cache County Study Investigators (2002) Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology 59:880–886PubMed

Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, Assaid C, Nessly ML, Norman BA, Baranak CC, Reines SA, Rofecoxib Protocol 078 study group (2005) A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 30:1204–1215CrossRefPubMed

ADAPT Research Group, Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S, Evans D, Green R, Mullan M (2008) Cognitive function over time in the Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 65:896–905CrossRefPubMed

Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57:1439–1443CrossRefPubMed

Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM (2009) Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam study. J Neurol Neurosurg Psychiatry 80:13–17CrossRefPubMed

Peila R, White LR, Masaki K, Petrovitch H, Launer LJ (2006) Reducing the risk of dementia: efficacy of long-term treatment of hypertension. Stroke 37:1165–1170CrossRefPubMed

Shah K, Qureshi SU, Johnson M, Parikh N, Schulz PE, Kunik ME (2009) Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. Am J Geriatr Pharmacother 7:250–261CrossRefPubMed

Egger SS, Bachmann A, Hubmann N, Schlienger RG, Krähenbühl S (2006) Prevalence of potentially inappropriate medication use in elderly patients: comparison between general medical and geriatric wards. Drugs Aging 23:823–837CrossRefPubMed

10.

Tune LE (2001) Anticholinergic effects of medication in elderly patients. J Clin Psychiatry 62:11–14PubMed

11.

Low LF, Anstey KJ, Sachdev P (2009) Use of medications with anticholinergic properties and cognitive function in a young-old community sample. Int J Geriatr Psychiatry 24:578–584CrossRefPubMed

12.

Ancelin ML, Artero S, Portet F, Dupuy AM, Touchon J, Ritchie K (2006) Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 332:455–459CrossRefPubMed

13.

Carrière I, Fourrier-Reglat A, Dartigues JF, Rouaud O, Pasquier F, Ritchie K, Ancelin ML (2009) Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Arch Intern Med 169:1317–1324CrossRefPubMed

14.

Campbell NL, Boustani MA, Lane KA, Gao S, Hendrie H, Khan BA, Murrell JR, Unverzagt FW, Hake A, Smith-Gamble V, Hall K (2010) Use of anticholinergics and the risk of cognitive impairment in an African American population. Neurology 75:152–159CrossRefPubMed

15.

Boustani MA, Campbell NL, Mungers S, Maidment I, Fox GC (2008) Impact of anticholinergics on the aging brain: a review and practical applications. Aging Health 4:311–320CrossRef

16.

Jessen F, Wiese B, Bachmann C, Eifflaender-Gorfer S, Haller F, Kölsch H, Luck T, Mösch E, van den Bussche H, Wagner M, Wollny A, Zimmermann T, Pentzek M, Riedel-Heller SG, Romberg HP, Weyerer S, Kaduszkiewicz H, Maier W, Bickel H, German Study on Aging, Cognition and Dementia in Primary Care Patients Study Group (2010) Prediction of dementia by subjective memory impairment: effects of severity and temporal association with cognitive impairment. Arch Gen Psychiatry 67:414–422CrossRefPubMed

17.

Chew ML, Mulsant BH, Pollock BG, Lehman ME, Greenspan A, Mahmoud RA, Kirshner MA, Sorisio DA, Bies RR, Gharabawi G (2008) Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc 56:1333–1341CrossRefPubMed

18.

Gilles C, Luthringer R (2007) Pharmacological models in healthy volunteers: their use in the clinical development of psychotropic drugs. J Psychopharmacol 21:272–282CrossRefPubMed

19.

Mesulam M, Shaw P, Mash D, Weintraub S (2004) Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Ann Neurol 55:815–828CrossRefPubMed

20.

Grothe M, Zaborszky L, Atienza M, Gil-Neciga E, Rodriguez-Romero R, Teipel SJ, Amunts K, Suarez-Gonzalez A, Cantero JL (2010) Reduction of basal forebrain cholinergic system parallels cognitive impairment in patients at high risk of developing Alzheimer’s disease. Cereb Cortex 20:1685–1695CrossRefPubMed

21.

Muth K, Schönmeyer R, Matura S, Haenschel C, Schröder J, Pantel J (2010) Mild cognitive impairment in the elderly is associated with volume loss of the cholinergic basal forebrain region. Biol Psychiatry 67:588–591CrossRefPubMed

22.

Herholz K (2008) Acetylcholine esterase activity in mild cognitive impairment and Alzheimer’s disease. Eur J Nucl Med Mol Imaging 35:25–29CrossRef

23.

DeKosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S, Bennett DA, Cochran EJ, Kordower JH, Mufson EJ (2002) Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 51:145–155CrossRefPubMed

24.

Ikonomovic MD, Abrahamson EE, Isanski BA, Wuu J, Mufson EJ, DeKosky ST (2007) Superior frontal cortex cholinergic axon density in mild cognitive impairment and early Alzheimer disease. Arch Neurol 64:1312–1317CrossRefPubMed

25.

Tracey KJ (2002) The inflammatory reflex. Nature 420:853–859CrossRefPubMed

26.

De Simone R, Ajmone-Cat MA, Carnevale D, Minghetti L (2005) Activation of α7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures. J Neuroinflammation 2:4CrossRefPubMed

27.

van Gool WA, van de Beek D, Eikelenboom P (2010) Systemic infection and delirium: when cytokines and acetylcholine collide. Lancet 375:773–775CrossRefPubMed

Title: Anticholinergic drug use and risk for dementia: target for dementia prevention
Authors: Frank Jessen
Hanna Kaduszkiewicz
Moritz Daerr
Horst Bickel
Michael Pentzek
Steffi Riedel-Heller
Michael Wagner
Siegfried Weyerer
Birgitt Wiese
Hendrik van den Bussche
Karl Broich
Wolfgang Maier
Publication date: 01-11-2010
Publisher: Springer-Verlag
Published in: European Archives of Psychiatry and Clinical Neuroscience / Issue Special Issue 2/2010
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-010-0156-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Anticholinergic drug use and risk for dementia: target for dementia prevention

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 2/2010

Is there a personalized medicine for mood disorders?

Ethical guidelines in psychiatric research

Psychiatric illness through the lifespan

Intervention in at-risk states for developing psychosis

Differential expression of presynaptic genes in a rat model of postnatal hypoxia: relevance to schizophrenia

State of psychiatry in Germany